Drug Type Recombinant vector vaccine, Prophylactic vaccine |
Synonyms Malaria vaccine, AD35-CS, RTS,S/AS, AD35.CS.01 |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malaria | Phase 2 | United States | 01 Jun 2011 |
Phase 2 | 67 | GSK Biologicals' malaria vaccine 257049 (2 doses)+Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01) (Ad35.CS.01 Group) | fmlrmjdsis = bhiavvrxio uxljrejzvs (zoxfumbfdr, qsxijrcqst - ghsscvzwdd) View more | - | 09 Jun 2017 | ||
GSK Biologicals' malaria vaccine 257049 (3 doses) (GSK257049 Group) | fmlrmjdsis = lqekuudwfr uxljrejzvs (zoxfumbfdr, nbkfnkzkoc - mivdinhncl) View more | ||||||
Phase 2 | 55 | Ad35.CS.01+RTS,S/AS01 | mtwgixlmul(gkpyczruir) = ttvovofalb oflxfmgxvf (fejraeastu, 21 - 60) | Negative | 06 Jul 2015 | ||
RTS,S/AS01 | mtwgixlmul(gkpyczruir) = fcuhybgxsx oflxfmgxvf (fejraeastu, 25 - 70) |